Sugi Predict

Sugi Predict / Compounds / SCHEMBL51166

SCHEMBL51166

SCHEMBL51166

Cc1noc(C)c1S(N)(=O)=O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA12 O43570 2/20 0.48
▸ CA1 P00915 2/20 0.48
▸ CA2 P00918 2/20 0.48
▸ CA9 Q16790 2/20 0.48
▸ KMT2A Q03164 2/20 0.47
▸ MAPT P10636 1/20 0.46
▸ BRD4 O60885 1/20 0.44
▸ BRD2 P25440 1/20 0.44
▸ BRD3 Q15059 1/20 0.44
▸ MAPK1 P28482 1/20 0.42
▸ ALDH1A1 P00352 2/20 0.41
▸ TSHR P16473 2/20 0.41
▸ GAA P10253 3/20 0.41
▸ HTT P42858 1/20 0.41
▸ NR3C1 P04150 2/20 0.40
▸ PGR P06401 1/20 0.40
▸ NR3C2 P08235 1/20 0.40
▸ L3MBTL1 Q9Y468 1/20 0.39
▸ POLB P06746 1/20 0.39
▸ MEN1 O00255 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5020955 0.79 KMT2A (0.49) KMT2AMAPTMAPK1ALDH1A1TSHR
SCHEMBL103900 0.77 KMT2A (0.47) KMT2AMAPTMAPK1ALDH1A1TSHR
SCHEMBL1323519 0.77 KMT2A (0.47) KMT2AMAPTMAPK1ALDH1A1TSHR
SCHEMBL2652292 0.77 KMT2A (0.47) KMT2AMAPTMAPK1ALDH1A1TSHR
SCHEMBL7621989 0.77 KMT2A (0.56) KMT2AMAPTALDH1A1TSHRHTT
SCHEMBL7038803 0.76 KMT2A (0.46) KMT2AMAPTMAPK1ALDH1A1TSHR
Hydrochloric Acid SCHEMBL27328972 0.76 KMT2A (0.46) KMT2AMAPTMAPK1ALDH1A1TSHR
SCHEMBL12922883 0.76 KMT2A (0.46) KMT2AMAPTMAPK1ALDH1A1TSHR
SCHEMBL8354304 0.74 KMT2A (0.57) KMT2AMAPTALDH1A1TSHRHTT
SCHEMBL12895708 0.74 KMT2A (0.45) KMT2AMAPTMAPK1ALDH1A1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 192 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3623372-B1 PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS VALO HEALTH INC (US) 2026-02-04 — — EP claimed
CN-118401505-A Heterocyclic compounds as SHP2 inhibitors, compositions comprising the same, and methods of use thereof 捷思英达控股有限公司 2024-07-26 — — CN claimed
WO-2024115549-A1 ARYL- AND HETEROARYL-SULFONAMIDE DERIVATIVES AS CCR8 MODULATORS IDORSIA PHARMACEUTICALS LTD (CH) 2024-06-06 — — WO claimed
EP-3092227-A1 BICYCLIC HETEROCYCLIC DERIVATIVES AS BROMODOMAIN INHIBITORS ORION CORPORATION (FI) 2016-11-16 — — EP claimed
WO-2015104653-A1 BICYCLIC HETEROCYCLIC DERIVATIVES AS BROMODOMAIN INHIBITORS AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) 2015-07-16 — — WO claimed
EP-1912988-B1 7-SUBSTITUTED AZA-INDAZOLES, COMPOSITIONS CONTAINING SAME, PRODUCTION METHOD AND USE THEREOF AVENTIS PHARMA SA (FR) 2014-04-16 — — EP claimed
US-8058290-B2 E.g., 1-[4-(3-amino-1H-pyrazolo[3,4-b]pyridin-6-yl)phenyl]-3-(2-fluoro-5-trifluoromethylphenyl)urea; and N-(6-{4-[3-(2-fluoro-5-trifluoromethylphenyl)ureido]-phenyl}-1H-pyrazolo[3,4-b]pyridin-3-yl))thiophene-3-carboxamide; kinase inhibitors, anticancer agents AVENTIS PHARMA S.A. (FR) 2011-11-15 — — US claimed
US-20090270383-A1 Novel Oxabispidine Compounds And Their Use In The Treatment Of Cardiac Arrhythmias ASTRAZENECA AB (SE) 2009-10-29 — — US claimed
US-20080182844-A1 7-Substituted Aza-Indazoles, Compositions Containing Same, Production Method and Use Thereof AVENTIS PHARMA S.A. (FR) 2008-07-31 — — US claimed
EP-1912988-A1 7-SUBSTITUTED AZA-INDAZOLES, COMPOSITIONS CONTAINING SAME, PRODUCTION METHOD AND USE THEREOF Aventis Pharma S.A. (FR) 2008-04-23 — — EP claimed
EP-1879877-A2 ANTIMICROBIAL AGENTS Ranbaxy Laboratories Limited (IN) 2008-01-23 — — EP claimed
WO-2007017577-A1 7-SUBSTITUTED AZA-INDAZOLES, COMPOSITIONS CONTAINING SAME, PRODUCTION METHOD AND USE THEREOF AVENTIS PHARMA S.A. (FR) 2007-02-15 — — WO claimed
WO-2006117762-A2 ANTIMICROBIAL AGENTS RANBAXY LABORATORIES LIMITED (IN) 2006-11-09 — — WO claimed
EP-4688148-A1 SELECTIVE RAPAMYCIN ANALOGS AND USES THEREOF Regeneron Pharmaceuticals, Inc. (US) 2026-02-11 — — EP disclosed
US-20240360153-A1 SELECTIVE RAPAMYCIN ANALOGS AND USES THEREOF REGENERON PHARMACEUTICALS, INC. (US) 2024-10-31 — — US disclosed
CN-118852135-A N-acyl sulfonamide compound, preparation method, pharmaceutical composition and application thereof 中国医学科学院药物研究所 2024-10-29 — — CN disclosed
WO-1998032741-A1 INHIBITORS OF FARNESYL PROTEIN TRANSFERASE ZENECA LIMITED (GB) 1998-07-30 — — WO disclosed
EP-0847391-A1 AROMATIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM ZENECA LIMITED (GB) 1998-06-17 — — EP disclosed
EP-0835246-A1 AROMATIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM ZENECA LIMITED (GB) 1998-04-15 — — EP disclosed
WO-1997000863-A1 AROMATIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM ZENECA LIMITED (GB) 1997-01-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090270383-A1 Novel Oxabispidine Compounds And Their Use In The Treatment Of Cardiac Arrhythmias KCNH1, RYR1, CACNA1E CA12 4476/4885CA1 2914/4885CA2 2459/4885
US-20240360153-A1 SELECTIVE RAPAMYCIN ANALOGS AND USES THEREOF FKBP14, FKBP4, FKBP1A CA12 4750/4885CA1 4864/4885CA2 4723/4885
US-20080182844-A1 7-Substituted Aza-Indazoles, Compositions Containing Same, Production Method and Use Thereof PRMT7, PRKACA, PRKX CA12 3621/4885CA1 2871/4885CA2 2838/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.